Summary
Carpenter Technology Corporation reported a decrease in net sales for the third quarter of fiscal year 2020, down 4% to $585.4 million, compared to the prior year. This decline was attributed to the ongoing Boeing 737 MAX production halt and the emerging COVID-19 pandemic, which impacted shipment volumes. Despite the top-line decrease, the company saw a strengthening product mix and increased sales in its Aerospace and Defense and Medical segments, excluding surcharge revenue. Net income for the quarter was $39.9 million, or $0.82 per diluted share, a decrease from $51.1 million, or $1.05 per diluted share, in the same period last year, partly due to an insurance recovery benefit in the prior year. For the first nine months of fiscal year 2020, net sales remained flat at $1,743.8 million. The company experienced significant growth in the Aerospace and Defense and Medical segments, driven by strong demand and improved product mix, which offset declines in Energy and Industrial & Consumer markets. The company is proactively managing the impact of COVID-19 through cost reduction initiatives and working capital management. While near-term visibility is limited, Carpenter Technology emphasizes its strong customer relationships and commitment to serving critical applications.
Financial Highlights
52 data points| Revenue | $585.40M |
| Cost of Revenue | $475.90M |
| Gross Profit | $109.50M |
| SG&A Expenses | $50.80M |
| Operating Income | $58.70M |
| Interest Expense | $4.90M |
| Net Income | $39.90M |
| EPS (Basic) | $0.82 |
| EPS (Diluted) | $0.82 |
| Shares Outstanding (Basic) | 48.10M |
| Shares Outstanding (Diluted) | 48.30M |
Key Highlights
- 1Net sales decreased by 4% to $585.4 million in Q3 FY2020 compared to the prior year, primarily due to the 737 MAX halt and COVID-19 impacts.
- 2Aerospace & Defense and Medical segments showed increased sales (excluding surcharges), indicating resilience in key markets.
- 3Net income for Q3 FY2020 was $39.9 million, a decrease from $51.1 million in Q3 FY2019, impacted by an insurance recovery in the prior year.
- 4For the nine-month period ended March 31, 2020, net sales were flat year-over-year at $1,743.8 million, with strong growth in Aerospace & Defense and Medical offsetting declines elsewhere.
- 5The company is implementing cost reduction measures and managing working capital in response to COVID-19 disruptions.
- 6A significant restructuring charge of $80 million to $100 million is expected in Q4 FY2020 related to exiting the Amega West business and closing two powder metals facilities.